News & Events
Insight Genetics to Present New Data on Subtyping Ovarian Cancer at 2015 American Society of Clinical Oncology Annual Meeting
Insight Genetics, a molecular diagnostics company focused on advancing precision medicine in cancer care, today announced that it will present new data on classifying distinct molecular subtypes of serous ovarian cancer at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
In a poster titled, “BL1 Gene Expression Subtype Predicts Outcome in Serous Ovarian Cancers,” the Insight Genetics team will present a novel approach in the diagnosis and treatment of ovarian cancer, applying the company’s proprietary Insight TNBCtypeTM algorithm to help classify which subtype of ovarian cancer a woman may have. The methodology builds upon subtyping technology for triple-negative breast cancer (TNBC) Insight Genetics exclusively licensed from Vanderbilt University Medical Center.
Based on prior observations of genetic abnormalities shared between TNBC and serous ovarian cancer, Insight Genetics applied Insight TNBCtype to existing serous ovarian cancer gene expression datasets and noted a similar distribution of molecular subtypes as previously found in TNBC. Moreover, based on treatment data studied to date, certain subtypes appear to have promise in predicting patient outcomes to various therapies in ovarian cancer.
“Similarities between triple-negative breast cancer and ovarian cancer have been observed in the past,” said Rob Seitz, Insight Genetics’ Chief Technology Officer. “It is exciting to see that the Insight TNBCtype subtyping system is showing similar patterns in ovarian cancer. This potentially will allow personalized therapies in breast cancer to be more rapidly adopted in ovarian cancer and vice versa.”
According to the American Cancer Society, about 21,000 women will be diagnosed with ovarian cancer this year, and 14,000 will die of the disease. Ovarian cancer has a higher mortality rate than many cancers because it has very few clear physical symptoms, which makes it challenging to detect in its early stages. Serous carcinoma is a type of epithelial ovarian cancer, which is the most common form of the disease, representing 85-90 percent of diagnoses.
The 2015 ASCO Annual Meeting will be held at McCormick Place in Chicago, Ill., from May 29 through June 2. Insight Genetics will present “BL1 Gene Expression Subtype Predicts Outcome in Serous Ovarian Cancers” during the Gynecologic Cancer Track session on Saturday, May 30, from 1:15-4:45 p.m. in S Hall A.